Author:
Guyton John R.,Slee April E.,Anderson Todd,Fleg Jerome L.,Goldberg Ronald B.,Kashyap Moti L.,Marcovina Santica M.,Nash Stephen D.,O'Brien Kevin D.,Weintraub William S.,Xu Ping,Zhao Xue-Qiao,Boden William E.
Funder
National Heart, Lung, and Blood Institute
Abbott Laboratories
Merck & Co.
Regeneron
Sanofi US
Genzyme Corporation, Isis Pharmaceuticals
Amgen
Amarin
GlaxoSmithKline
Merck
Roche
Abbott
AstraZeneca
Eli Lilly
Sanofi
Subject
Cardiology and Cardiovascular Medicine
Reference22 articles.
1. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy;N Engl J Med,2011
2. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment;Haynes;Eur Heart J,2013
3. Armitage J. HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Presented at: American College of Cardiology Annual Scientific Sessions; March 9, 2013; San Francisco, CA.
4. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study;Lee;J Am Coll Cardiol,2009
5. Extended-release niacin or ezetimibe and carotid intima-media thickness;Taylor;N Engl J Med,2009
Cited by
158 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献